SCHEMBL3208875

SCHEMBL3208875

C#Cc1cc(Cl)ccc1C(=O)NC.c1cc2cc-2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
P2RX1 P51575 1/20 0.40
FLT1 P17948 2/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
SMO Q99835 1/20 0.38
SERPINE1 P05121 1/20 0.38
NR4A2 P43354 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
GRIK1 P39086 1/20 0.37
NUDT1 P36639 2/20 0.37
ALOX15 P16050 1/20 0.37
HSD17B1 P14061 1/20 0.36
MALT1 Q9UDY8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921256 0.82 DCLRE1B (0.48) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL3213553 0.81 IKBKB (0.43) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL3224539 0.77 CYP11B2 (0.61) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL3208710 0.72 P2RX7 (0.37) NPC1RAB9AKMT2ATDP1KDM4E
SCHEMBL4043786 0.72 GAA (0.53) ALDH1A1POLBPDK2
SCHEMBL8576509 0.72 SMN1; SMN2 (0.57) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL3787454 0.71 ALDH1A1 (0.50) MEN1KMT2ATDP1P2RX1KDM4E
SCHEMBL28787885 0.71 KDM4E (0.46) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL4154496 0.70 KDM4E (0.67) MEN1NPC1RAB9AKMT2ATDP1
SCHEMBL29833777 0.70 KDM4E (0.67) MEN1NPC1RAB9AKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed
WO-2006022955-A2 TOPOISOMERASE INHIBITORS PROPHARMACON, INC. (US) 2006-03-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B MEN1 2335/4885NPC1 2916/4885RAB9A 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.